Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Beovu Generic Name & Formulations
Legal Class
Rx
General Description
Brolucizumab-dbll 6mg/0.05mL; soln for oph intravitreal inj; preservative-free.
Pharmacological Class
Vascular endothelial growth factor (VEGF) inhibitor.
How Supplied
Single-dose vial (w. needle), single-dose prefilled syringe—1
Manufacturer
Generic Availability
NO
Beovu Indications
Indications
Neovascular (wet) age-related macular degeneration (AMD). Diabetic macular edema (DME).
Beovu Dosage and Administration
Adult
Give by intravitreal inj. AMD: 6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12 weeks. DME: 6mg (0.05mL) every 6 weeks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12 weeks.
Children
Not established.
Beovu Contraindications
Contraindications
Ocular or periocular infections. Active intraocular inflammation.
Beovu Boxed Warnings
Not Applicable
Beovu Warnings/Precautions
Warnings/Precautions
Must only be administered by a qualified physician. Monitor for endophthalmitis, retinal detachments, retinal vasculitis and/or retinal vascular occlusion, elevation in IOP, and perfusion of optic nerve head following inj. Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Advise females of reproductive potential to use effective contraception during and for ≥1 month after the last dose. Pregnancy. Nursing mothers: not recommended (during and for ≥1 month after the last dose).
Beovu Pharmacokinetics
See Literature
Beovu Interactions
Not Applicable
Beovu Adverse Reactions
Adverse Reactions
Vision blurred, cataract, conjunctival hemorrhage, eye pain, vitreous floaters; hypersensitivity reactions.
Beovu Clinical Trials
See Literature
Beovu Note
Not Applicable
Beovu Patient Counseling
See Literature
